Skip to main content
An official website of the United States government
Español
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

afamitresgene autoleucel

(A-fam-ih-TRES-jeen AW-toh-LOO-sel)
A treatment used for adults with synovial sarcoma that has the MAGE-A4 antigen and has spread to other parts of the body or cannot be removed by surgery. It is used in patients who have certain HLA-A*02 antigens and have received chemotherapy. It is also being studied in the treatment of other types of cancer. Afamitresgene autoleucel is made using a patient’s T cells (a type of immune system cell). A special T-cell receptor that can recognize the MAGE-A4 antigen is added to the T cells in the laboratory. These changed T cells are then grown in large numbers in the laboratory and given back to the patient by infusion. Afamitresgene autoleucel binds to the MAGE-A4 antigen, which is found on some types of cancer cells. This helps the body’s immune system kill cancer cells. Afamitresgene autoleucel is a type of cellular immunotherapy. Also called Tecelra.
Search NCI's Dictionary of Cancer Terms